MICRUS ENDOVASCULAR CORP

Form 4

August 21, 2007

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

OMB Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

OMB APPROVAL

response...

if no longer subject to Section 16. Form 4 or Form 5

obligations

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940 See Instruction

1(b).

(Last)

(City)

(Print or Type Responses)

1. Name and Address of Reporting Person 2
HBM BIOVENTURES CAYMAN
LTD

2. Issuer Name and Ticker or Trading Symbol

5. Relationship of Reporting Person(s) to Issuer

(First)

(Middle)

MICRUS ENDOVASCULAR CORP [MEND]

(Check all applicable)

CENTENNIAL TOWERS, 3RD

(Street)

(State)

3. Date of Earliest Transaction (Month/Day/Year) 08/17/2007

Director X__ 10% Owner Officer (give title _ Other (specify below)

FLOOR, 2454 WEST BAY ROAD

4. If Amendment, Date Original

6. Individual or Joint/Group Filing(Check

Applicable Line)

Filed(Month/Day/Year)

X Form filed by One Reporting Person Form filed by More than One Reporting

GRAND CAYMAN, E9

(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Own

1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactio Code (Instr. 8)	4. Securities Acquired n(A) or Disposed of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code V	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		
Common Stock	08/17/2007		S	100	D	\$ 23.44	1,761,596	D	
Common Stock	08/17/2007		S	100	D	\$ 23.45	1,761,496	D	
Common Stock	08/17/2007		S	200	D	\$ 23.48	1,761,296	D	
Common Stock	08/17/2007		S	300	D	\$ 23.5	1,760,996	D	
Common Stock	08/17/2007		S	100	D	\$ 23.51	1,760,896	D	

Edgar Filing: MICRUS ENDOVASCULAR CORP - Form 4

Common Stock	08/17/2007	S	100	D	\$ 23.52	1,760,796	D
Common Stock	08/17/2007	S	200	D	\$ 23.54	1,760,596	D
Common Stock	08/17/2007	S	100	D	\$ 23.56	1,760,496	D
Common Stock	08/17/2007	S	122	D	\$ 23.75	1,760,374	D
Common Stock	08/17/2007	S	181	D	\$ 23.83	1,760,193	D
Common Stock	08/17/2007	S	300	D	\$ 23.84	1,759,893	D
Common Stock	08/17/2007	S	19	D	\$ 23.85	1,759,874	D
Common Stock	08/17/2007	S	100	D	\$ 23.89	1,759,774	D
Common Stock	08/17/2007	S	800	D	\$ 23.91	1,758,974	D
Common Stock	08/17/2007	S	200	D	\$ 23.92	1,758,774	D
Common Stock	08/17/2007	S	100	D	\$ 23.93	1,758,674	D
Common Stock	08/17/2007	S	100	D	\$ 23.94	1,758,574	D
Common Stock	08/20/2007	S	2,200	D	\$ 23.1	1,756,374	D
Common Stock	08/20/2007	S	200	D	\$ 23.11	1,756,174	D
Common Stock	08/20/2007	S	400	D	\$ 23.13	1,755,774	D
Common Stock	08/20/2007	S	300	D	\$ 23.14	1,755,474	D
Common Stock	08/20/2007	S	300	D	\$ 23.15	1,755,174	D
Common Stock	08/20/2007	S	500	D	\$ 23.16	1,754,674	D
Common Stock	08/20/2007	S	100	D	\$ 23.17	1,754,574	D
Common Stock	08/20/2007	S	400	D	\$ 23.19	1,754,174	D
	08/20/2007	S	500	D	\$ 23.2	1,753,674	D

Edgar Filing: MICRUS ENDOVASCULAR CORP - Form 4

Common Stock							
Common Stock	08/20/2007	S	200	D	\$ 23.21	1,753,474	D
Common Stock	08/20/2007	S	100	D	\$ 23.23	1,753,374	D
Common Stock	08/20/2007	S	100	D	\$ 23.25	1,753,274	D
Common Stock	08/20/2007	S	400	D	\$ 23.28	1,752,874	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. onNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	7. Titl Amou Under Securi (Instr.	nt of lying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Owne Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address	Relationships							
	Director	10% Owner	Officer	Other				
HBM BIOVENTURES CAYMAN LTD								
CENTENNIAL TOWERS, 3RD FLOOR		X						
2454 WEST BAY ROAD		Λ						
GRAND CAYMAN, E9								

Reporting Owners 3

Edgar Filing: MICRUS ENDOVASCULAR CORP - Form 4

Signatures

/s/ John Arnold, Chairman and Managing Director

08/21/2007

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Remarks:

Related transactions effected by the Reporting Person on August 17, 2007 and August 20, 2007 are reported on additional For Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 4